Latest Content

ACP's new obesity guidelines name semaglutide and tirzepatide as first-line drugs in a 4-tier hierarchy, with weight-regain warnings for all agents.

A CMS proposed rule would make the Medicare Drug Price Negotiation Program permanent, covering up to 20 drugs per year starting in 2029.

Mark Malesker, PharmD, discusses the clinical evidence, drug interaction risks, and formulary challenges surrounding cannabinoid use for sleep disorders.

Worse kidney function and higher proteinuria at biopsy predicted significantly greater health care use over 2 years in patients with IgA nephropathy.

After decades of neglect, malnutrition-related diabetes, or type 5, is finally getting the research, recognition, and clinical framework it demands.

I-SPY 2.2 of rilvegostomig plus trastuzumab deruxtecan in breast cancer treatment cut chemo use while exposing access issues and disparities.

Real-world DME care falls short from missed anti-VEGF loading; sustained delivery, neuroprotection, and better primary care coordination promise gains.

The lead investigator for SUCCESSOR-2 discusses the potency of a potential successor to pomalidomide in treatment of multiple myeloma, with survival outcomes that rival CAR T-cell therapy.

EHA 2026 late-breaking data featured phase 3 trials in CLL, AML, multiple myeloma, and myelofibrosis, plus early CAR T data in B-cell lymphoma and ITP.